TissueLabs
Develops a biofabrication platform integrating 3D bioprinters and tissue-specific biomaterials for creating lab-grown tissues and organs, accelerating research in drug discovery, disease modeling, and regenerative medicine.
- CEO / Founder
- Gabriel Liguori
- Team Size
- 11-50
- Stage
- Active
- Total Funding
- $1.1M
- Latest Round
- Pre-Seed
- Key Investors
- Mergus Ventures; MIT Angels; BioTools Innovator; Venture Leaders Biotech; MassChallenge Switzerland
Technology & Products
Key Products
TissueStart (extrusion-based 3D bioprinter); TissuePro (advanced extrusion-based bioprinter); TissueRay (masked stereolithography bioprinter); Tissue-specific dECM hydrogels (15 tissue types); MatriWell (3D printed cell culture platform)
Technological Advantage
Verified advantage: Proprietary mixing module (Mixtrusor) supports five independent printheads with coaxial/triaxial capabilities, allowing precise control and automation in multi-material bioprinting. Defensible through patents and trade secrets.
Differentiation
Value Proposition
Reduces time and cost for tissue engineering research by providing ready-to-use kits and high-precision bioprinters, enabling scalable production of complex 3D tissue structures for applications like drug testing and organ fabrication.
How They Differentiate
Offers a full-stack platform with both hardware (bioprinters like TissuePro) and materials (15 tissue-specific hydrogels), unlike competitors focused solely on printers or therapeutics; 3x broader material range and proprietary mixing technology for enhanced precision.
Market & Competition
Target Customers
Researchers, scientists, and medical innovators in academia, pharmaceutical companies, and research institutions
Industry Verticals
Biotechnology; Pharmaceuticals; Regenerative Medicine; Research and Development; Cultured Meat
Competitors
Aspect Biosystems, Allevi, Xlife sciences, ROKIT Healthcare
Growth & Milestones
Growth Metrics
Revenue estimated at $1.4M annually with 14 employees and 8% employee growth; products used by thousands of scientists in over 30 countries.
Major Milestones
Launched TissuePro bioprinter in 2024; Moved headquarters from Brazil to Switzerland in 2021; Secured $800k pre-seed funding in 2023; Recognized as a top 10 growth startup in biotechnology
Notable Customers
King’s College London; University of Zurich (Switzerland); Indiana University; National Institute of Health and Medical Research (Inserm, France)